[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359511-105":59,"doc-detail-359511-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pten-loss-promotes-pi3k-phosphorylation-and-epha2srcp-pi3ky962-complex-assembly-to-drive-tumorigenesis-research-article","PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis - Research Article","","Loss of the tumor suppressor PTEN drives cancer progression and resistance, yet targeted options for PTEN-deficient tumors are lacking. This study identifies a druggable mechanism whereby PTEN loss induces PI3Kβ phosphorylation. Using BioID, the authors reveal a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962, which promotes oncogenic pERK/c-MYC and pAKT signaling through EPHA2/SRC complex formation. They develop a selective p-PI3KβY962 antibody, show growth suppression in PTEN-null models, and demonstrate dasatinib-mediated reduction of p-PI3KβY962 and tumor progression, supporting p-PI3KβY962 as a biomarker and therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pten-loss-promotes-pi3k-phosphorylation-and-epha2srcp-pi3ky962-complex-assembly-to-drive-tumorigenesis-research-article/359511/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pten-loss-promotes-pi3k-phosphorylation-and-epha2srcp-pi3ky962-complex-assembly-to-drive-tumorigenesis-research-article/359511.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does PTEN loss promote tumorigenesis in this study?","Question",{"text":112,"@type":113},"PTEN loss induces PI3Kβ phosphorylation, leading to formation of an EPHA2/SRC/p-PI3KβY962 complex that activates oncogenic pERK/c-MYC and pAKT pathways to drive tumorigenesis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What experimental approach was used to uncover the PI3Kβ–EPHA2 interaction?",{"text":117,"@type":113},"The study used BioID interactome mapping to identify a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells driven by p-PI3KβY962.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategy does the study propose for PTEN-deficient cancers?",{"text":121,"@type":113},"The work proposes targeting p-PI3KβY962 as a druggable target and biomarker, and it shows that dasatinib (an FDA-approved SRC/EPHA2 inhibitor) reduces p-PI3KβY962 and inhibits tumor progression specifically in PTEN-null tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359511,1790216651,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","ReseaRch aRticle  \nPTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis   \nShuang Tang1,2,3,4,5, Qian Zhou1,2, Johann S. Bergholz3,4, Tao Jiang3,4, Weihua Wang3,4, Renlei Ji3,4, Wendi Huang6, Jiachen Wu1,2,7, Yutong Li3,4, Xiaochun Wan8, Xiadi He3,4, Qianchen Jing3, Menghong Sun8, Jared L. Johnson3,9, 10, Tomer M. Yaron-Barir9, 11, 12, Da-Qiang Li1,2, Bo Dai13, Zefeng Wang14, Xiaoling Li15, Lewis C. Cantley3, 9, 10, Thomas M. Roberts3,4, and Jean J. Zhao3,4  \nLoss of the tumor-suppressor PTEN drives cancer progression and therapeutic  \nresistance, yet no targeted therapies exist for PTEN-deficient tumors. In this study, we identify a critical druggable mechanism in which PTEN loss induces PI3Kβ phosphorylation for tumorigenesis. Using the BioID interactome, we uncovered a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962 . PTEN functions as a tyrosine phosphatase that normally dephosphorylates p-PI3KβY962 . In PTEN-deficient contexts, enhanced p-PI3KβY962 forms a complex with EPHA2 and SRC, in which both kinases contribute to PI3Kβ phosphorylation, activating oncogenic pERK/c-MYC and pAKT pathways. We developed a selective p-PI3KβY962 antibody detecting p-PI3KβY962 in PTEN-deficient tumors across preclinical models and clinical tumor specimens. Disrupting p-PI3KβY962 suppressed tumor growth in multiple PTEN-null models. Dasatinib, an FDA-approved SRC/EPHA2 inhibitor, effectively reduced p-PI3KβY962 and inhibited tumor progression in PTEN-null but not PTEN wild-type tumors. These findings establish p-PI3KβY962 as a druggable target and biomarker for developing targeted therapy in PTEN-deficient cancers beyond conventional PI3K kinase inhibition.  \nSIgNIfICANCE: We revealed a critical new mechanism that PTEN loss induces PI3Kβ phosphorylation and EPHA2/SRC/p-PI3KβY962 complex signaling to drive tumorigenesis. This work directs pharmaceutical development of p-PI3KβY962 inhibitors and biomarker-driven clinical trials repurposing dasatinib for PTEN-deficient solid tumor treatment, with potential to significantly improve outcomes of broad patients with PTEN-deficient tumors.  \nintRoduction  \nThe PI3K pathway is hyperactivated across human cancers through genetic PI3K mutations or loss of the PTEN tumorsuppressor (1–3), making the PTEN–PI3K axis a critical therapeutic target. Significantly, the p110α catalytic isoform of PI3K (PI3Kα), encoded by the PIK3CA gene, is frequently activated through hotspot mutations in diverse cancer types. Recently, the FDA granted approval for alpelisib (BYL719), the first selective PI3Kα inhibitor, in combination with endocrine therapy for treating advanced or metastatic breast cancers harboring PIK3CA mutations (4) . This milestone underscores the potential for targeting oncogenic PI3K signaling with isoform-specific precision therapies in genetically defined patient populations.  \n1Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts. 5Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. 6Bio-Med Big Data Center, Chinese Academy of Sciences Key Laboratory of Computational Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health, Shanghai, China. 7State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, China. 8Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. 9Department of Cell Biology, Harvard Medical School, Boston, Massachusetts. 10Meyer Cancer Center, Weill Cornell Medicine, New York, New York. 11Engla","cbCaipQ7S3ckD0RQ","https://ap.wps.com/l/cbCaipQ7S3ckD0RQ","pdf",14657963,"English","# Introduction\n## PTEN–PI3K axis and PI3Kβ dependency\n# Results (Mechanistic findings)\n## PTEN loss induces p-PI3KβY962 phosphorylation\n## PI3Kβ–EPHA2 interaction and EPHA2/SRC complex signaling\n# Therapeutic translation\n## p-PI3KβY962 antibody and in vivo tumor suppression\n## Dasatinib as SRC/EPHA2 inhibitor for PTEN-null tumors\n# Significance","[{\"question\":\"How does PTEN loss promote tumorigenesis in this study?\",\"answer\":\"PTEN loss induces PI3Kβ phosphorylation, leading to formation of an EPHA2/SRC/p-PI3KβY962 complex that activates oncogenic pERK/c-MYC and pAKT pathways to drive tumorigenesis.\"},{\"question\":\"What experimental approach was used to uncover the PI3Kβ–EPHA2 interaction?\",\"answer\":\"The study used BioID interactome mapping to identify a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells driven by p-PI3KβY962.\"},{\"question\":\"What therapeutic strategy does the study propose for PTEN-deficient cancers?\",\"answer\":\"The work proposes targeting p-PI3KβY962 as a druggable target and biomarker, and it shows that dasatinib (an FDA-approved SRC/EPHA2 inhibitor) reduces p-PI3KβY962 and inhibits tumor progression specifically in PTEN-null tumors.\"}]","PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis - Research Article | PDF",1790137076,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9a57990d2f3859a896836fdc8ae7a1b.webp",983,1315,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a91cc651b3a4c5b8619c845c3db8a07a.webp",982,1314,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efa82e9408486fd1ed3e494b530a95cc.webp",981,1312,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b4253728cc94bc0b54f9b29254f7cf3.webp",980,1311]